tiprankstipranks
Trending News
More News >
Bristol-Myers Squibb (BMY)
NYSE:BMY
US Market

Bristol-Myers Squibb (BMY) Drug Pipeline

Compare
11,960 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Pembrolizumab, Pumitamig
Non-Small Cell Lung Cancer (Nsclc)
Phase III
Not Yet Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Jan 21, 2026
Durvalumab, Pumitamig
Non-Small Cell Lung Cancer (Nsclc)
Phase III
Not Yet Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Jan 21, 2026
Nivolumab, Bms-986525
Relapsed/Refractory Small Cell Lung Cancer
Phase I/II
Not Yet Recruiting
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Jan 06, 2026
Atezolizumab, Bevacizumab, Ipilimumab, Pumitamig
Hepatocellular Carcinoma (Hcc)
Phase I/II
Not Yet Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Dec 17, 2025
Nivolumab, Ipilimumab, Pumitamig, Cabozantinib
Advanced Renal Cell Carcinoma (Rcc)
Phase I/II
Not Yet Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Dec 17, 2025
Karxt
Schizophrenia
Phase III
Not Yet Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents
Dec 16, 2025
Karxt, Karx-Ec
Irritability Associated With Autism Spectrum Disorder
Phase III
Not Yet Recruiting
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
Dec 10, 2025
Karxt, Karx-Ec
Irritability Associated With Autism Spectrum Disorder
Phase III
Not Yet Recruiting
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
Dec 09, 2025
Bms-985521
Healthy Volunteers
Phase I
Recruiting
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
Dec 02, 2025
Gemcitabine, Nab-Paclitaxel, Mfolfirinox, Pumitamig
Pancreatic Ductal Adenocarcinoma (Pdac)
Phase II
Recruiting
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Nov 20, 2025

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Bristol-Myers Squibb (BMY) have in its pipeline
      BMY is currently developing the following drugs: Pembrolizumab, Pumitamig, Durvalumab, Pumitamig, Nivolumab, Bms-986525. These drug candidates are in various stages of clinical development as the company works toward FDA approval.